0000000000746801

AUTHOR

P. Evrard

showing 2 related works from this author

Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Resear…

2021

Abstract Background Epidemiological studies in atrial fibrillation (AF) illustrate that clinical complexity increase the risk of major adverse outcomes. We aimed to describe European AF patients’ clinical phenotypes and analyse the differential clinical course. Methods We performed a hierarchical cluster analysis based on Ward’s Method and Squared Euclidean Distance using 22 clinical binary variables, identifying the optimal number of clusters. We investigated differences in clinical management, use of healthcare resources and outcomes in a cohort of European AF patients from a Europe-wide observational registry. Results A total of 9363 were available for this analysis. We identified three …

RegistrieResearch Reportmedicine.medical_specialtyMajor adverse outcomeCardiovascular risk factorsCluster analysisRisk FactorsInternal medicineClinical phenotypeAtrial FibrillationEpidemiologyHumansMedicineRegistriesCluster analysiAtrial fibrillation; Clinical management; Clinical phenotypes; Cluster analysis; Major adverse outcomes; Humans; Phenotype; Registries; Research Report; Risk Factors; Atrial FibrillationClinical managementbusiness.industryProportional hazards modelRisk FactorHazard ratioRAtrial fibrillationClinical phenotypesMajor adverse outcomesGeneral Medicinemedicine.diseaseAtrial fibrillationConfidence intervalPhenotypeCohortMedicineObservational studybusinessResearch ArticleHumanBMC Medicine
researchProduct

Exceptional LAS Requests in Eurotransplant: Analysis of an 8-year Effort to Improve Lung Allocation for Precarious Patients

2020

PURPOSE: Following introduction of the lung allocation score (LAS) in 2011, Eurotransplant member centers can apply for an exceptional LAS (eLAS) if the calculated LAS insufficiently reflects the perceived transplant benefit for a patient, specifically in case of primary pulmonary hypertension group 1 and 4; combined lung+non-renal transplantation; rare diseases; or extracorporeal support. Each eLAS proposal is evaluated by a LAS Review Board, consisting of ≥3 lung transplant experts, which subsequently declines or approves the eLAS request in consensus of ≥3 votes. In case of a lower than accepted score, predefined business rules to assign LAS percentiles are used. METHODS: A retrospective…

Pulmonary and Respiratory MedicineTransplantationPediatricsmedicine.medical_specialtyLungbusiness.industryAcceptance rateSciences bio-médicales et agricolesmedicine.diseaseGroup BObstructive lung diseaseTransplantationmedicine.anatomical_structuremedicineRetrospective analysisSurgeryRestrictive lung diseaseCardiology and Cardiovascular MedicinebusinessLung allocation score
researchProduct